Advertisement

Endometriumkarzinom

  • G. Bastert
  • S. D. Costa

Zusammenfassung

Als Präkanzerosen des Endometriumkarzinoms gelten die adenomatösen Hyperplasien, die in bis zu 30% der Fälle in ein invasives Karzinom münden können:
  1. 1.

    einfache Hyperplasie: zystisch, ohne Atypien, kann das ganze Endometrium erfassen oder lokalisiert bleiben (= Endometrium-Polyp); führt in 0–1% zu Karzinomen

     
  2. 2.

    komplexe Hyperplasie: adenomatös, ohne Atypien, Entartung in 3%

     
  3. 3.

    atypische einfache Hyperplasie: zystisch, wie 1, zusätzlich Atypien, Entartung in 8%.

     
  4. 4.

    atypische komplexe Hyperplasie: adenomtös, auch Adenocarcinoma in situ — der Begriff „Adenocarcinoma insitu“ sollte nicht mehr verwandt werden, da die Diagnose schwer reroduzierbar ist und die Behandlung sich von der komplexen Hyperplasie mit Atypien nicht unterscheidet: wie 2. Zusätzlich Atypien, Entartung in 29% der Fälle.

     

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Aapro M, Bolis G, Chevallier B, van der Burg MEL, Poveda A, de Oliveira C, Pawinski A, Sahmoud T, Pecorelli S (1994) An EORTC-GCCG randomized phase II trail of doxorubicin (DOX) versus DOX-Cisplatin (CDDP) in endometrial carcinoma. Proc Annu Meet AmSoc Clin Oncol 13: 275 (Abstract 885)Google Scholar
  2. 2.
    Berman ML, Berek JS (990) Uterine Carcinomas. In: Haskell CM (ed): Cancer Treatment 3rd. ed, WB Saunders Co, Philadelphia, pp 338–348Google Scholar
  3. 3.
    Bonte J, Ide P, Billiet G, Wynants P (1981) Tamoxifen as a possible chemotherapeutic agent in endometrial adenocarcinoma.Gynecol Oncol 11: 140–161PubMedCrossRefGoogle Scholar
  4. 4.
    Bruckman JE, Goodman RL, Murthy A, Marck A (1978) Combined irradiation and surgery in the treatment of stage II carcinoma of the endometrium. Cancer 42: 1146–1151PubMedCrossRefGoogle Scholar
  5. 5.
    Brunner KW (1987) Effects and side effects of chemotherapy in endometrial cancer. In Schulz KD, King RJB, Pollow K, Taylor RW (eds): Endometrial cancer. Zuckschwerdt, München, pp 181–190Google Scholar
  6. 6.
    Childers JM, Brzechffa PR, Hatch KD, Surwit EA (1993) Laparoscopically assisted surgical staging (LASS) of endometrial cancer. Gynecol Oncol 51: 33–38PubMedCrossRefGoogle Scholar
  7. 7.
    Creasman WT, McCarty KS, Barton TK (1980) Clinical correlates of estrogen-and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol 55: 363–370PubMedGoogle Scholar
  8. 8.
    dePalo G, Kenda R, Andreola S, Bandieramonte G, Luciani L, Stefanon B (1992) A retrospective analysis of 53 patients with pathologic stage II and III endometrial carcinoma. Tumori 68: 341–347Google Scholar
  9. 9.
    Deppe G, Cohen CJ, Bruckner HW (1980) Treatment of advanced endometrial adenocarcinoma with cis-Dichlorodiamine Platinum (II) after intensive prior therapy. Gynecol Oncol 10: 51–54PubMedCrossRefGoogle Scholar
  10. 10.
    Deppe G (1984) Chemotherapy of endometrial carcinoma. In. Deppe G (ed) Chemotherapy of gynecologic cancer. Liss, New York, pp 139–150Google Scholar
  11. 11.
    DiSaia P, Creasman WT (1989) Clinical Gynecologic Oncology, 3rd, (ed), CV Mosby Co, St. Louis, pp 161–197Google Scholar
  12. 12.
    Edmonson JH, Krook JE, Hilton JF, Malkasian GD, Everson LK, Jefferies JA, Mail-liard JA (1987) Randomized phase II studies of cisplatin and combination of cyclophosphamide-doxorubicin-cisplatin (CAP) in patients with progestin-refractory advanced endometrial carcinoma. Gynecol Oncol 28: 20–24CrossRefGoogle Scholar
  13. 13.
    Ehrlich CE, Cleary RE, Young PCM (1978) The use of progesterone receptors in the management of recurrent endometrial cancer. In: Brush MG, King RJB, Taylor RW (eds) Endometrial cancer. Bailliere-Tindall, LondonGoogle Scholar
  14. 14.
    Ehrlich CE, Young PCM, Stehman FB, Sutton GP, Alford WM (1988) Steroid receptors and clinical outcome in patients with adenocarcinoma of the endometrium. Am J Obstet Gynecol 158: 796–805PubMedGoogle Scholar
  15. 15.
    Fournier D v, Junkermann H, Anton HW (1987) Indikation zur Radiotherapie beim Kollum-and Korpuskarzinom nach Operation. Gynäkologe 20: 222–227Google Scholar
  16. 16.
    Gallagher CJ, Oliver RTD, Oram DH, Fowler CG, Blake PR, Mantell BS, Slevin ML, Hope-Stone HF (1991) A new treatment for endometrial cancer with gonadotrophin releasing-hormone analogue. Br J Obstet Gynecol 98: 1037–1041CrossRefGoogle Scholar
  17. 17.
    Goff BA, Goodman A, Muntz HG, Fuler AF, Nikrui N, Rice LW (1994) Surgical stage IV endometrial carcinoma: A study of 47 cases. Gynecol Oncol 52: 237–240PubMedCrossRefGoogle Scholar
  18. 18.
    Greven K, Olds W (1987) Radiotherapy in the management of endometrial carcinoma with cervical involvement. Cancer 60: 1737–1740PubMedCrossRefGoogle Scholar
  19. 19.
    Grigsby PW, Perez CA, Camel HM, Kao MS, Galakatos AE (1985) Stage II carcinoma of the endometrium: Results of therapy and prognostic factors. Int J Radiat Oncol Biol Phys 11: 1915–1923PubMedCrossRefGoogle Scholar
  20. 20.
    Hacker NF (1989) Uterine cancer. In: Berek JS, Hacker NF (eds) Practical gynecologic oncology. Williams & Wilkins, Baltimore, pp 285–326Google Scholar
  21. 21.
    Horton K, Beeg CB, Arseneault J, Bruckner H, Creech R, Hahn RG (1978) Comparison of adriamycin with cyclophosphamide in patients with advanced endometrial cancer. Cancer Treat Rep 62: 159–161PubMedGoogle Scholar
  22. 22.
    Jick SS, Walker AM, Jich H (1993) Oral contraceptives and endometrial cancer. Obstet Gynecol 82: 931–935PubMedGoogle Scholar
  23. 23.
    Kinsella TJ, Bloomer WD, Lavin PT, Knapp RC (1980) Stage II endometrial carcinoma: 10-year follow-up of combined radiation and surgical treatment. Gynecol Oncol 10: 290–297PubMedCrossRefGoogle Scholar
  24. 24.
    Kohorn EI (1976) Gestagens and endometrial carcinoma. Gynecol Oncol 4: 398–411PubMedCrossRefGoogle Scholar
  25. 25.
    Kolstad P (1987) The role of radiation in the treatment of endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds): Endometrial cancer. Zuckschwerdt, München, pp 129–135Google Scholar
  26. 26.
    Lentz S, Brady M, Soper J, Major F, Reid G (1994) High dose megestrol acetate in advanced or recurrent endometrial carcinoma. A Gynecologic Oncology Group ( GOG) study. Proc Annu Meet Am Soc Clin Oncol 13: 260Google Scholar
  27. 27.
    Lewis GC, Slack NH, Mortel R, Bross IDJ (9174) Adjuvant progestogen therapy in the primary definitive treatment of endometrial cancer. Gynecol Oncol 2: 368–376Google Scholar
  28. 28.
    Long HJ, Pfeifle DM, Wieand HS, Krook JE, Edmonson JH, Buckner JC (1988) Phase II evaluation of carboplatin in advaced endometrial carcinoma. J Natl Cancer Inst 80: 276–278PubMedCrossRefGoogle Scholar
  29. 29.
    Lynch HT, Follet KL, Lynch PM, Albano WA, Mailliard JL, Pierson RL (1979) Family history in an oncology clinic. JAMA 242: 1268–1272Google Scholar
  30. 30.
    Marchetti DL, Piver MS, Tsukada Y, Reese P (1986) Prevention of vaginal recurrence of stage I endometrial adenocarcinoma with postoperative vaginal radiation. Obstet Gynecol 67: 399–402PubMedGoogle Scholar
  31. 31.
    Marziale P, Atlante G, Pozzi M, Diotallevi, Iacovelli A (1989) 426 cases of stage I endometrial carcinoma: A clinicopathological analysis. Gynecol Oncol 32: 278–281Google Scholar
  32. 32.
    Muss HB, Blessing JA, Hatch KD, Soper JT, Webster KD, Kemp GM (1990) Methotrexate in advanced endometrial carcinoma. Am J Clin Oncol 13 (1): 61–63PubMedCrossRefGoogle Scholar
  33. 33.
    Piver MS, Barlow JJ, Lurain JR, Blumenson LE (1980) Medroxyprogesterone acetate (Depo-Provera) vs. Hydroxyprogesterone caproate ( Delalutin) in women with metastatic endometrial adenocarcinoma. Cancer 45: 268–272Google Scholar
  34. 34.
    Piver MS, Marchetti DL (1989) Endometrial Carcinoma. In: Piver MS (ed) Manual of gynecology oncology and gynecology. Little, Brown, Boston, pp 87–101Google Scholar
  35. 35.
    Potish RA, Twiggss LB, Adcock LL, Savage JE, Levitt SH, Prem KA (1985) Para-aortic lymph node radiotherapy in cancer of the uterine corpus. Obstet Gynecol 65(2):251— 256Google Scholar
  36. 36.
    Quinn MA, Cauchi M, Fortune D (1985) Endometrial carcinoma: Steroid receptors and response to medroxyprogesterone acetate. Gynecol Oncol 21: 314–319Google Scholar
  37. 37.
    Reifenstein EC (1974) The treatment of advanced endometrial cancer with hydroxyprogesterone caproate. Gynecol Oncol 2: 377–414PubMedCrossRefGoogle Scholar
  38. 38.
    Rustowski J, Kupsc W (1982) Factors influencing the results of radiotherapy in cases of inoperable endometrial cancer. Gynecol Oncol 14: 185–193PubMedCrossRefGoogle Scholar
  39. 39.
    Sause WT, Fuller DB, Smith WG, Johnson GH, Plenk HP, Menlove RB (1990) Analysis of preoperative intracavitary cesium application versus postoperative external beam radiation in stage I endometrial carcinoma. Int J Radiat Oncol Biol Phys 18: 1011–1017PubMedCrossRefGoogle Scholar
  40. 40.
    Schmidt-Matthiesen H, Bastert G (1993) Endometriumkarzinom. In. Gynäkologische Onkologie, 4 Aufl. Schattauer, Stuttgart New York, pp 33–48Google Scholar
  41. 41.
    Schulz KD, Schmidt-Rhode P, Zippel HH, Sturm G (1987) New concepts of adjuvant drug treatment in endometrial cancer. In: Schulz KD, King RJB, Pollow K, Taylor RW (eds): Endometrial cancer. Zuckschwerdt, München, pp 169–180Google Scholar
  42. 42.
    Seski JC, Edwards CL, Copeland LJ, Gershenson DM (1981) Hexamethylmelamine chemotherapy for disseminated endometrial cancer. Obstet Gynecol 58 (3): 361–363PubMedGoogle Scholar
  43. 43.
    Seski JC, Edwards CL, Herson J, Rutledge FN (1982) Cisplatin chemotherapy for disseminated endometrial cancer. Obstet Gynecol 59 (2): 225–228PubMedGoogle Scholar
  44. 44.
    Sevin BU (1986) Primär operative Therapie des Korpuskarzinoms. Gynäkologe 19: 88–93PubMedGoogle Scholar
  45. 45.
    Slavik M, Petty WM, Blessing JA, Creasman WT, Homesley HD (1984) Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: A Gynecologic Oncology Group Study. Cancer Treat Rep 68: 809–811Google Scholar
  46. 46.
    Surwitt EA, Fowler WC Jr, Rogoff EE, Jelovsek F, Parker RT, Creasman WT (1979) Stage II carcinoma of the endometrium. Int J Radiat Oncol Biol Phys 5: 323326Google Scholar
  47. 47.
    Sutton GP, Blessing JA, Homesley HD, McGuire WP, Adcock L (1994) Phase II study of ifosfamide and mesna in refractory adenocarcinoma of the endometrium. Cancer 73: 1453–1455PubMedCrossRefGoogle Scholar
  48. 48.
    Swenerton KD (1980) Treatment of advanced endometrial adenocarcinoma with tamoxifen. Cancer Treat Rep 64: 806–811Google Scholar
  49. 49.
    Thigpen JT, Buchsbaum HJ, Mangan C, Blessing JA (1979) Phase II trial of adriamycin in the treatment of advanced or recurrent endometrial carcinoma: A Gynecological Oncology Group Study. Cancer Treat Rep 63: 21–27Google Scholar
  50. 50.
    Thigpen JT, DiSaia PJ, Blessing JA, Homesley HD, Lagasse LD (1984) Phase II trial of cisplatin as second-line chemotherapy in patients with advanced or recurrent endometrial carcinoma. Am J Clin Oncol 7: 253–256PubMedCrossRefGoogle Scholar
  51. 51.
    Thigpen JT, Vance R, Lambuth B, Ablducci L, Khansur T, Blessing JA, McGehee R (1987) Chemotherapy for advanced or recurrent gynecologic cancer. Cancer 60: 2104–2116PubMedCrossRefGoogle Scholar
  52. 52.
    Thigpen JT, Blessing JA, Ball H, Hanjani P, Manetta A, Homesley HD (1988) Hexamethylmelamine as first-line chemotherapy in the treatment of advanced or recurrent carcinoma of the endometrium: A phase II trial of the Gynceologic Oncology Group. Gynecol Oncol 31: 435–438Google Scholar
  53. 53.
    Thigpen JT, Blessing JA, Homesley HD, Creasman WT, Sutton G (1989) Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: A Gynecologic Oncology Group Study. Gynecol Oncol 33: 68–70Google Scholar
  54. Vaeth JM, Fontanesi J, Tralins AH, Chauser BM (1988) External radiation therapy of stage I cancer of the endometrium: A need for reappraisal of this adjunctive modality. Int J Radiat Oncol Biol Phys 15: 1291–1297Google Scholar
  55. 55.
    Varia M, Rosenman J, Halle J, Walton L, Currie J, Fowler W (1987) Primary radiation therapy for medically inoperable patients with endometrial carcinoma — Stages I—II. Int J Radiat Oncol Biol Phys 13: 11–15PubMedCrossRefGoogle Scholar
  56. 56.
    Vergote I, Korstad K, Abeler V, Kolstad P (1989) A randomized trial of adjuvant progesteron in early endometrial cancer. Cancer 64: 1011–1016PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1995

Authors and Affiliations

  • G. Bastert
  • S. D. Costa

There are no affiliations available

Personalised recommendations